Source abstract
Abstract
Abstract Catalytically inactive CRISPR‐Cas13 (dCas13)‐based base editors can achieve the conversion of adenine‐to‐inosine (A‐to‐I) or cytidine‐to‐uridine (C‐to‐U) at the RNA level, however, the large size of dCas13 protein limits its in vivo applications. Here, a compact and efficient RNA base editor (ceRBE) is reported with high in vivo editing efficiency. The larger dCas13 protein is replaced with a 199‐amino acid EcCas6e protein, derived from the Class 1 CRISPR family involved in pre‐crRNA processing, and conducted optimization for toxicity and editing efficiency. The ceRBE efficiently achieves both A‐to‐I and C‐to‐U base editing with low transcriptome off‐target in HEK293T cells. The efficient repair of the DMD Q1392X mutation (68.3±10.1%) is also demonstrated in a humanized mouse model of Duchenne muscular dystrophy (DMD) after AAV delivery, achieving restoration of expression for gene products. The study supports that the compact and efficient ceRBE has great potential for treating genetic diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · RNA regulation and disease · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
HuidaGene Therapeutics Co. Ltd. 6th Floor, Unit 3, Building 5, No. 160 Basheng Road, Pudong New Area Shanghai 200131 China
Institute of Neuroscience State Key Laboratory of Neuroscience Key Laboratory of Primate Neurobiology CAS Center for Excellence in Brain Science and Intelligence Technology Chinese Academy of Science 320 Yueyang Road Shanghai 200031 China
Department of Neurology First Affiliated Hospital Fujian Medical University No. 20 Chazhong Road Fuzhou 350005 China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China
References (31)
Show source-provided references